Trending News
Welcome to our list of the most viewed stock market news.
Updated every minute, this automated list is generated based on real-time analytics to bring you the news articles that are receiving the most attention right now.
Whether you're an investor, a trader, or simply curious about the financial markets, you'll find this list to be a valuable resource for keeping tabs on market trends and company updates.
Navigate through the top news and stay informed with the most current insights in the stock market world.
Astera Labs (ALAB) reported strong Q4 FY2024 results with record quarterly revenue of $141.1 million, up 25% QoQ and 179% YoY. Full-year revenue reached $396.3 million, marking a 242% increase from the previous year.
Q4 GAAP performance showed a gross margin of 74.0% and net income of $24.7 million ($0.14 per diluted share). Non-GAAP Q4 results included operating income of $48.4 million and net income of $66.5 million ($0.37 per diluted share).
For Q1 FY2025, the company projects revenue between $151-155 million with a GAAP gross margin of approximately 74%. Growth was primarily driven by Aries PCIe Retimer products and Taurus Smart Cable Modules, with expectations for 2025 to be a breakout year as all four product families contribute to revenue.
- Record Q4 revenue of $141.1M, up 25% QoQ and 179% YoY
- FY2024 revenue of $396.3M, up 242% YoY
- Strong Q4 non-GAAP operating margin of 34.3%
- Q1 FY2025 guidance projects continued growth with revenue of $151-155M
- High gross margins maintained at 74%
- Full-year GAAP operating loss of $116.1M
- GAAP net loss of $83.4M for FY2024
- GAAP operating margin of -29.3% for FY2024

IonQ (NYSE: IONQ) and General Dynamics Information Technology (GDIT) have announced a strategic partnership to bring quantum computing solutions to government and defense sectors. The collaboration will combine GDIT's technical expertise with IonQ's quantum technology to develop advanced quantum processing and networking applications.
The partnership will focus on quantum AI extensions, resource optimization, and anomaly detection. Earlier, both companies worked with a major intelligence agency to enhance data analysis capabilities. This announcement builds on IonQ's federal sector presence, following their recent $54.5 million contract with the U.S. Air Force Research Lab (AFRL) and a $5.7 million contract with ARLIS for a multi-node, blind quantum computing system initiative.
- Secured new strategic partnership with GDIT for government and defense sector expansion
- Recently won $54.5M contract with U.S. Air Force Research Lab
- Additional $5.7M contract with ARLIS for quantum computing system
- Expanding market presence in federal sector
- None.

Fluence Energy (FLNC) reported Q1 2025 results with revenue of $186.8 million, representing a 49% decrease year-over-year. The company improved its GAAP gross profit margin to 11.4% from 10.0% in the same quarter last year. Net loss increased to $57.0 million from $25.6 million year-over-year.
The company has lowered its FY2025 guidance, with revenue now expected between $3.1-3.7 billion (previously $3.6-4.4 billion) and Adjusted EBITDA projected at $70-100 million (down from $160-200 million). The guidance reduction is primarily due to delayed contract signings in Australia and lower expected gross margins on recent contracts.
Notable developments include a record backlog of $5.1 billion and the issuance of $400 million in Convertible Senior Notes due 2030. Total cash position stands at $654.4 million as of December 31, 2024, an increase of $135.7 million from the previous quarter.
- Record backlog of $5.1 billion
- Improved gross profit margin to 11.4% from 10.0% YoY
- Strong cash position of $654.4 million, up $135.7 million QoQ
- Successful raise of $400 million through convertible notes
- Revenue decreased 49% YoY to $186.8 million
- Net loss increased to $57.0 million from $25.6 million YoY
- FY2025 revenue guidance lowered by $600 million at midpoint
- Adjusted EBITDA guidance reduced by $95 million at midpoint
- Lower expected gross margins on recently signed contracts
Axcelis Technologies (NASDAQ: ACLS) reported Q4 2024 financial results with revenue of $252.4 million and diluted EPS of $1.54. The company's full-year 2024 performance showed revenue of $1.02 billion, down from $1.13 billion in 2023. Systems revenue decreased to $782.6 million from $883.6 million in 2023.
Despite revenue decline, gross margin improved to 44.7% in 2024 from 43.5% in 2023. Net income for 2024 was $201 million with diluted EPS of $6.15, compared to $246.3 million and $7.43 EPS in 2023. For Q1 2025, Axcelis expects revenues of approximately $185 million and diluted EPS of $0.38.
Management anticipates a near-term cyclical digestion period as customers absorb mature node capacity investments, particularly in China. The company plans to focus on product innovation, cost management, and customer collaboration to position for future growth.
- Q4 gross margin improved to 46.0% from 42.9% in Q3 2024
- Q4 operating profit increased to $54.5M from $46.9M in Q3 2024
- Full-year gross margin improved to 44.7% from 43.5% in 2023
- Full-year revenue declined 9.7% to $1.02B from $1.13B in 2023
- Systems revenue decreased 11.4% to $782.6M from $883.6M in 2023
- Net income dropped 18.4% to $201M from $246.3M in 2023
- Q1 2025 guidance shows significant sequential decline to $185M revenue
- Expected Q1 2025 EPS of $0.38 represents substantial decrease from Q4's $1.54
Vertex Pharmaceuticals reported strong financial results for Q4 and full year 2024, with full-year product revenue reaching $11.02 billion, a 12% increase from 2023. The company provided 2025 revenue guidance of $11.75 to $12.0 billion.
Key highlights include FDA approvals for ALYFTREK for cystic fibrosis patients ages 6+ and JOURNAVX for moderate-to-severe acute pain. Q4 2024 product revenue increased 16% to $2.91 billion, with U.S. revenue up 17% to $1.84 billion and international revenue up 14% to $1.07 billion.
The company announced leadership changes, with COO Stuart Arbuckle retiring July 1, 2025. CFO Charlie Wagner will assume the additional role of COO, while Duncan McKechnie will become CCO. Cash position stood at $11.2 billion as of December 31, 2024, down from $13.7 billion year-over-year due to the Alpine acquisition and share repurchases.
- Full-year product revenue increased 12% to $11.02 billion
- Q4 product revenue grew 16% to $2.91 billion
- FDA approvals for two new drugs: ALYFTREK and JOURNAVX
- Strong cash position of $11.2 billion
- Positive 2025 revenue guidance of $11.75-12.0 billion
- GAAP net loss of $536 million in 2024 compared to $3.6 billion profit in 2023
- Cash position decreased by $2.5 billion year-over-year
- Increased operating expenses and tax expenses
- Higher R&D and SG&A expenses year-over-year

Global Interactive Technologies (NASDAQ:GITS), the media-tech company behind FANTOO, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq's Listing Qualifications Department on February 10, 2025, that it has met the necessary criteria by maintaining a share price above $1.00 for at least 10 consecutive business days, specifically from January 27 through February 7, 2025. This development ensures GITS will continue to be listed and traded on the Nasdaq exchange, resolving their previous bid price deficiency matter.
- Regained Nasdaq listing compliance, eliminating delisting risk
- Maintained share price above $1.00 for required period
- Continues to trade on major exchange, ensuring better liquidity and market access
- Recent history of share price weakness that led to compliance issues

Beyond Air (NASDAQ: XAIR) reported fiscal Q3 2025 results with revenues of $1.1 million, showing a 34% increase from the previous quarter and 175% year-over-year growth. The company received CE Mark for LungFit PH in Europe and Market Authorization in Australia, expanding its global market presence.
Key developments include six new U.S. hospital starts in Q3, partnerships with two Middle East distributors, and a triggered $1 million milestone payment from Getz Healthcare. The company reported cash and equivalents of $10.9 million with total debt of $11.8 million. Cash runway is expected to extend well into 2026.
Operating expenses decreased significantly, with R&D expenses down to $3.0 million from $6.8 million year-over-year, and SG&A expenses reduced to $7.7 million from $9.8 million. The quarter's cash burn was $7.6 million.
- Revenue growth of 34% quarter-over-quarter to $1.1 million
- CE Mark approval for LungFit PH in Europe
- Market authorization secured in Australia
- Six new U.S. hospital implementations in Q3
- $1 million milestone payment from Getz Healthcare partnership
- Significant reduction in operating expenses
- Cost of revenue ($1.3M) exceeded revenue ($1.1M)
- Quarterly cash burn of $7.6 million
- Other expenses increased by $2.1 million due to debt retirement loss
Medpace Holdings (MEDP) reported Q4 2024 financial results with revenue increasing 7.7% to $536.6 million. Net new business awards were $529.7 million, representing a net book-to-bill ratio of 0.99x. GAAP net income rose significantly to $117.0 million ($3.67 per diluted share), with a net income margin of 21.8%.
For full-year 2024, revenue grew 11.8% to $2,109.1 million, with net new business awards of $2,230.0 million and a book-to-bill ratio of 1.06x. The company's backlog increased 3.2% to $2,902.2 million. EBITDA increased 32.5% to $480.2 million.
Looking ahead, Medpace provided 2025 guidance projecting revenue between $2.110-2.210 billion and GAAP net income of $378.0-402.0 million. The company also announced a $600 million increase to its stock repurchase program.
- Q4 2024 revenue increased 7.7% YoY to $536.6 million
- Q4 GAAP net income increased 49.4% YoY to $117.0 million
- Full-year 2024 revenue grew 11.8% to $2,109.1 million
- EBITDA margin improved to 24.9% in Q4 2024 from 19.2% in Q4 2023
- Board approved $600 million increase to share repurchase program
- Q4 2024 net new business awards decreased 13.8% YoY to $529.7 million
- Q4 2024 book-to-bill ratio declined to 0.99x from previous year
- 2025 revenue guidance suggests slower growth of 0.0% to 4.8%
Harmonic (NASDAQ: HLIT) reported record Q4 2024 results with total revenue of $222.2 million, up 33% year over year. The company achieved record quarterly Adjusted EBITDA of $71.8 million. Broadband segment revenue reached $171.0 million, while Video segment revenue was $51.1 million.
The company announced a new $200 million share repurchase program through February 2028, doubling its previous program. Q4 GAAP net income was $38.1 million ($0.32 per share), and non-GAAP net income was $52.4 million ($0.45 per share). The company's cash position strengthened to $101.5 million.
For 2025 guidance, Harmonic expects total revenue between $585-645 million, with GAAP net income per share of $0.19-$0.45. Management noted that 2025 Broadband revenue guidance reflects temporary shifts in customer deployment timing during the transition to Unified DOCSIS 4.0, with growth expected to resume in 2026.
- Record quarterly revenue of $222.2M, up 33% YoY
- Record quarterly Adjusted EBITDA of $71.8M
- Broadband segment revenue increased 48% YoY to $171.0M
- New $200M share repurchase program authorized
- Strong cash position of $101.5M, up from $84.3M YoY
- Improved gross margins: 56.1% vs 49.0% YoY
- Video segment revenue declined slightly to $51.1M from $51.9M YoY
- GAAP net income per share decreased to $0.32 from $0.72 YoY
- Bookings decreased to $150.0M from $196.5M YoY
- Backlog and deferred revenue declined to $496.3M from $653.2M YoY
- Conservative 2025 Broadband guidance due to deployment timing shifts